Catheterization and Cardiovascular Interventions · 2006 · 127 citations · 5 references
MedicineCardiologySurgeryCardiothoracic SurgeryDrug DeliveryInterventional CardiologyCoronary AngioplastyCoronary Artery DiseaseCoronary Artery SurgeryPercutaneous Coronary InterventionStent PlacementAntiproliferative AgentsCoronary StentingGraftingMri CompatibilityStent BiomaterialsStent Graft PlacementVascular StentingVasomotion
The first-in-human fully bioabsorbable drug-eluting stent (BVS poly-L-lactic acid everolimus-eluting coronary stent) implantation was performed at Auckland City Hospital, New Zealand as part of the ABSORB trial. There were no adverse events in-hospital or by 1 month. A stent that supports the vessel when needed, delivers an antiproliferative drug then disappears has theoretical advantages with regard to CT and MRI compatibility, restored vessel vasomotion, and facilitated future percutaneous intervention or surgical grafting to the treated site.
5
Willem J. van der Giessen, A. Michael Lincoff, Robert S. Schwartz et al. · Circulation · 1996 · 853 citations · Full text
Natural Sciences, Bioengineering, Biomedical Engineering +17
Initial and 6-Month Results of Biodegradable Poly- <i>l</i> -Lactic Acid Coronary Stents in Humans
Hideo Tamai, Keiji Igaki, Eisho Kyo et al. · Circulation · 2000 · 801 citations
Medicine, Cardiology, Surgery +17